Pablo Angeles Tacchino
@pabloangelest.bsky.social
Médico Nefrólogo
Pinned
Ok oficialmente nuevo en está red. Pero todo los ex #nephtwitter . Están por acá #separeceatwitter
Reposted by Pablo Angeles Tacchino
Great day-by-day recaps of #KidneyWk from the #NephJC team—perfect if you missed a session. Begin here 👉🏻 www.nephjc.com/news/2025/11...
Kidney Week in Houston: Day 3 — NephJC
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
www.nephjc.com
November 11, 2025 at 5:19 PM
Great day-by-day recaps of #KidneyWk from the #NephJC team—perfect if you missed a session. Begin here 👉🏻 www.nephjc.com/news/2025/11...
Reposted by Pablo Angeles Tacchino
large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
November 6, 2025 at 10:30 PM
large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
Reposted by Pablo Angeles Tacchino
Finally, a large group of patients are those with heterozygous COL4A3 and COL4A4 variants who do well long term with only microscopic hematuria. The problem is that you don't know which patients will fall into this bucket and which will fall into the buckets above by genotyping alone. #KidneyWk
November 6, 2025 at 6:39 PM
Finally, a large group of patients are those with heterozygous COL4A3 and COL4A4 variants who do well long term with only microscopic hematuria. The problem is that you don't know which patients will fall into this bucket and which will fall into the buckets above by genotyping alone. #KidneyWk
Reposted by Pablo Angeles Tacchino
Trials coming out already!
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
November 5, 2025 at 8:33 PM
Trials coming out already!
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
Reposted by Pablo Angeles Tacchino
Reposted by Pablo Angeles Tacchino
Next up Zigakibart in IgAN treated for 76 weeks.
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
September 25, 2025 at 10:04 PM
Next up Zigakibart in IgAN treated for 76 weeks.
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
Reposted by Pablo Angeles Tacchino
September 26, 2025 at 2:03 AM
Reposted by Pablo Angeles Tacchino
It wouldn't be an @edgarvlermamd.bsky.social lecture without a Spiderman ref #GlomCon
September 26, 2025 at 1:45 AM
It wouldn't be an @edgarvlermamd.bsky.social lecture without a Spiderman ref #GlomCon
Reposted by Pablo Angeles Tacchino
Fervenza has been asked about galactose deficient IgA1. He says he is going to be nice but then says he has nothing nice to say about KDIGO.
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
September 26, 2025 at 2:14 AM
Fervenza has been asked about galactose deficient IgA1. He says he is going to be nice but then says he has nothing nice to say about KDIGO.
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
Reposted by Pablo Angeles Tacchino
👩🏻 75-year-old woman
- History of epilepsy
📈 Creatinine: 2.36 → 7.3 mg/dL in 9 days
🧪 Positive MPO ANCA (61.06)
- History of epilepsy
📈 Creatinine: 2.36 → 7.3 mg/dL in 9 days
🧪 Positive MPO ANCA (61.06)
September 19, 2025 at 7:46 PM
👩🏻 75-year-old woman
- History of epilepsy
📈 Creatinine: 2.36 → 7.3 mg/dL in 9 days
🧪 Positive MPO ANCA (61.06)
- History of epilepsy
📈 Creatinine: 2.36 → 7.3 mg/dL in 9 days
🧪 Positive MPO ANCA (61.06)
Up next!
New AHA/ACC hypertension guidelines #NephJC
@ahascience.bsky.social @accintouch.bsky.social
New AHA/ACC hypertension guidelines #NephJC
@ahascience.bsky.social @accintouch.bsky.social
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
AIM: The “2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for
the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults”
retires and replaces the “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults.” METHODS: A comprehensive literature search was conducted from December 2023 to June 2024 to
identify clinical studies, reviews, and other evidence performed on human subjects
that were published since February 2015 in English from MEDLINE (through PubMed),
EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and
other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to create a living, working document
updating current knowledge in the field of high blood pressure aimed at all practicing
primary care and specialty clinicians who manage patients with hypertension.
www.ahajournals.org
September 3, 2025 at 4:37 AM
After 8 years, a new AHA/ACCA hypertension guideline
📊 Proposes cardiovascular risk assessment using the PREVENT calculator.
Urine albumin-to-creatinine ratio in all hypertensive patients.
Plasma aldosterone-to-renin ratio to detect hyperaldosteronism.
📊 Proposes cardiovascular risk assessment using the PREVENT calculator.
Urine albumin-to-creatinine ratio in all hypertensive patients.
Plasma aldosterone-to-renin ratio to detect hyperaldosteronism.
The 🆕 AHA/ACC/Multisociety #ClinicalGuideline on high blood pressure provides updated recommendations for clinicians on the prevention, detection, evaluation, and management of high blood pressure in adults.
Get the details ➡️ https://bit.ly/47xv5o7 #Hypertension #JACC #CardioSky #MedSky
Get the details ➡️ https://bit.ly/47xv5o7 #Hypertension #JACC #CardioSky #MedSky
August 15, 2025 at 12:53 AM
After 8 years, a new AHA/ACCA hypertension guideline
📊 Proposes cardiovascular risk assessment using the PREVENT calculator.
Urine albumin-to-creatinine ratio in all hypertensive patients.
Plasma aldosterone-to-renin ratio to detect hyperaldosteronism.
📊 Proposes cardiovascular risk assessment using the PREVENT calculator.
Urine albumin-to-creatinine ratio in all hypertensive patients.
Plasma aldosterone-to-renin ratio to detect hyperaldosteronism.
Reposted by Pablo Angeles Tacchino
HDF over HD: New report from the EuDial working group
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
August 8, 2025 at 12:08 PM
HDF over HD: New report from the EuDial working group
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Reposted by Pablo Angeles Tacchino
HiLo, HiLo it's off to work we go! ⛏️
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
High or Low Phosphate? Are we Missing the (P)oint? — NephJC
This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?
www.nephjc.com
August 5, 2025 at 1:08 AM
HiLo, HiLo it's off to work we go! ⛏️
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
so the HiLo study was unremarkable in the treatmet of Hyperphosphahtemia, will the Phosphate trial tell us something different?
July 11, 2025 at 12:52 PM
so the HiLo study was unremarkable in the treatmet of Hyperphosphahtemia, will the Phosphate trial tell us something different?
Reposted by Pablo Angeles Tacchino
The Pathology Lesion Patterns of Podocytopathies: How and why?
#ERA25 🇦🇹 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/35281116/
#ERA25 🇦🇹 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/35281116/
June 6, 2025 at 11:57 PM
The Pathology Lesion Patterns of Podocytopathies: How and why?
#ERA25 🇦🇹 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/35281116/
#ERA25 🇦🇹 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/35281116/
Reposted by Pablo Angeles Tacchino
June 5, 2025 at 9:54 AM
Reposted by Pablo Angeles Tacchino
The first #ERA25 simultaneous pub
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
June 5, 2025 at 9:54 AM
The first #ERA25 simultaneous pub
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
Reposted by Pablo Angeles Tacchino
www.nejm.org/doi/full/10....
Very exciting to hear about this ground breaking clinical trial at #era2025
Very exciting to hear about this ground breaking clinical trial at #era2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | NEJM
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr...
www.nejm.org
June 5, 2025 at 10:14 AM
www.nejm.org/doi/full/10....
Very exciting to hear about this ground breaking clinical trial at #era2025
Very exciting to hear about this ground breaking clinical trial at #era2025
In Heart Failure, Finerenone 20-40mg vs placebo, ↓ cardiorenal risks, effect appears to be independient of the renal risk, ↓ albuminuria more Benefit in renal outcome
PostHoc of FINEARTS-HF
JACC 2025. doi.org/10.1016/j.jc...
PostHoc of FINEARTS-HF
JACC 2025. doi.org/10.1016/j.jc...
April 7, 2025 at 2:07 PM
In Heart Failure, Finerenone 20-40mg vs placebo, ↓ cardiorenal risks, effect appears to be independient of the renal risk, ↓ albuminuria more Benefit in renal outcome
PostHoc of FINEARTS-HF
JACC 2025. doi.org/10.1016/j.jc...
PostHoc of FINEARTS-HF
JACC 2025. doi.org/10.1016/j.jc...
Different guidelines hypertension targets comparisson. HYPERTENSION 2025. #Hypertension
March 17, 2025 at 1:59 PM
Different guidelines hypertension targets comparisson. HYPERTENSION 2025. #Hypertension
Reposted by Pablo Angeles Tacchino
Reposted by Pablo Angeles Tacchino
📢 New CREDENCE data in NDT:
SGLT2i in CKD and T2D:
✅ ↓ Insulin initiation/dose intensification by 19%
✅ ↑ Reductions in insulin dose by up to 49%
✅ Consistent ↓ in insulin use down to GFR of 30ml/min in whom glycosuric effect is minimal
academic.oup.com/ndt/advance-...
SGLT2i in CKD and T2D:
✅ ↓ Insulin initiation/dose intensification by 19%
✅ ↑ Reductions in insulin dose by up to 49%
✅ Consistent ↓ in insulin use down to GFR of 30ml/min in whom glycosuric effect is minimal
academic.oup.com/ndt/advance-...
March 2, 2025 at 10:18 AM
📢 New CREDENCE data in NDT:
SGLT2i in CKD and T2D:
✅ ↓ Insulin initiation/dose intensification by 19%
✅ ↑ Reductions in insulin dose by up to 49%
✅ Consistent ↓ in insulin use down to GFR of 30ml/min in whom glycosuric effect is minimal
academic.oup.com/ndt/advance-...
SGLT2i in CKD and T2D:
✅ ↓ Insulin initiation/dose intensification by 19%
✅ ↑ Reductions in insulin dose by up to 49%
✅ Consistent ↓ in insulin use down to GFR of 30ml/min in whom glycosuric effect is minimal
academic.oup.com/ndt/advance-...